TABLE 2.
Clinical characteristics of patients in the four groups defined by Rscore and Cscore
| Characteristics | RSCS (n = 169) | RSCR (n = 99) | RRCS (n = 88) | RRCR (n = 154) |
|---|---|---|---|---|
| Age (y) | 41.06 ± 12.80 | 40.16 ± 12.64 | 44.75 ± 13.00 | 45.56 ± 13.98 |
| Histologic type | ||||
| Astrocytoma | 52 (30.77%) | 40 (40.40%) | 25 (28.41%) | 75 (48.70%) |
| Oligoastrocytoma | 36 (21.30%) | 28 (28.28%) | 20 (22.73%) | 44 (28.57%) |
| Oligodendroglioma | 80 (47.34%) | 31 (31.31%) | 43 (48.86%) | 35 (22.73%) |
| Unknown | 1 (0.59%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) |
| Histologic grade | ||||
| G2 | 86 (50.89%) | 58 (58.59%) | 39 (44.32%) | 64 (41.56%) |
| G3 | 82 (48.52%) | 40 (40.40%) | 49 (55.68%) | 90 (58.44%) |
| Unknown | 1 (0.59%) | 1 (1.01%) | 0 (0.00%) | 0 (0.00%) |
| IDH status | ||||
| Mutant | 161 (95.27%) | 89 (89.90%) | 78 (88.64%) | 85 (55.19%) |
| WT | 8 (4.73%) | 9 (9.09%) | 10 (11.36%) | 67 (43.51%) |
| Unknown | 0 (0.00%) | 1 (1.01%) | 0 (0.00%) | 2 (1.30%) |
| 1p/19q codeletion | ||||
| Non‐codeletion | 96 (56.80%) | 80 (80.81%) | 38 (43.18%) | 129 (83.77%) |
| Codeletion | 73 (43.20%) | 19 (19.19%) | 50 (56.82%) | 25 (16.23%) |
| Unknown | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) |
| MGMT promoter | ||||
| Unmethylated | 17 (10.06%) | 17 (17.17%) | 8 (9.09%) | 48 (31.17%) |
| Methylated | 152 (89.94%) | 82 (82.83%) | 80 (90.91%) | 106 (68.83%) |
| Unknown | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) |
| TERT promoter | ||||
| Mutant | 39 (23.08%) | 13 (13.13%) | 31 (35.23%) | 47 (30.52%) |
| WT | 54 (31.95%) | 47 (47.47%) | 23 (26.14%) | 34 (22.08%) |
| Unknown | 76 (44.97%) | 39 (39.39%) | 34 (38.64%) | 73 (47.40%) |
Abbreviations: RRCR, RT‐resistant and chemotherapy‐resistant; RRCS, RT‐resistant and chemotherapy‐sensitive; RSCR, RT‐sensitive and chemotherapy‐resistant; RSCS, RT‐sensitive and chemotherapy‐sensitive.